Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Internal Medicine
•
Hematology
Is there a role at this time for chemo-immunotherapy in the upfront treatment of classic Hodgkin lymphoma?
Although not approved, for example, are you every using AVD-nivolumab?
Related Questions
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
What is your preferred salvage therapy for patients with follicular lymphoma who relapsed within 24 months of completing front-line chemoimmunotherapy (POD24) and will proceed to high-dose therapy with Auto-SCT?
How do you approach frontline treatment for an elderly patient with adult T-cell leukemia-lymphoma (ATL)?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?